Inclusivity of patients in early phase breast cancer clinical trials☆

被引:0
|
作者
Sinha, A. [1 ]
Barwell, L. [1 ]
Jeffery, H. [1 ,2 ]
Peterson, Z. [1 ,2 ]
Shifa, B. [1 ,2 ]
Attia, M. [2 ,3 ]
Badawy, K. [1 ]
Purushotham, A. [1 ,2 ]
机构
[1] Kings Coll London, London, England
[2] Guys & St Thomas NHS Fdn Trust, London, England
[3] Cairo Univ, Fac Med, Dept Gen Surg, Cairo, Egypt
来源
JOURNAL OF CANCER POLICY | 2024年 / 41卷
关键词
Diversity; Clinical Trials; Recruitment; Ethnicity; UNDER-REPRESENTATION; STREPTOMYCIN;
D O I
10.1016/j.jcpo.2024.100494
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Studies have shown that certain groups of patients are underrepresented in clinical trials including non-Caucasian ethnicity, poor fluency in English, low socioeconomic status, older age, neurodivergence, and large Body Mass Index (BMI). There is a need to ensure adequate representation of these groups so that the results of any trial accurately reflect the population. The aim of this study was to review the pathway of patients recruited into two early phase breast cancer clinical and determine the inclusivity of patients from the aforementioned sub-groups. Methods: The Breast Cancer Research Database was reviewed, and the characteristics of all patients who were screened for eligibility in two early phase clinical trials was examined. The English Indices of Deprivation was used to populate the Index of Multiple Deprivation (IMD) for each patient using their postcode. Results: In total, 392 patients were eligible to participate, between September 2020 to May 2023. Of these, 144 (36.7 %) were recruited to these two trials. In all, 100 % of patients eligible for these trials were approached and screened for participation. Eligible patients had a mean age of 53.5 years. Recruited patients were younger on average than those not recruited (49.1 years vs 56.0 years, p<0.0001). Only one recruited patient required an interpreter, compared with 24 (9.7 %%) of those who were not recruited (p<0.001). There was no difference in the IMD (p=0.38), BMI (p=0.34) and neurodiversity (p=0.10) between patients recruited into clinical trials and those who were not. Conclusion: Older age and poor fluency in the English language remain barriers to participation in early-phase clinical trials despite implementing a clear pathway to trial recruitment. There is a pressing need to address these barriers by raising awareness, improve appropriate training and providing comprehensive trial information to patients in the language of their choice.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Increasing accrual of minority patients in breast cancer clinical trials
    Trant, Amelia A.
    Walz, Lucas
    Allen, Whitney
    DeJesus, Jose
    Hatzis, Christos
    Silber, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) : 499 - 505
  • [42] Enrollment of older metastatic breast cancer patients in clinical trials
    Bringuier, Michael
    Carton, Matthieu
    Levy, Christelle
    Patsouris, Anne
    Pasquier, David
    Debled, Marc
    Rigal, Olivier
    Jacot, William
    Goncalves, Anthony
    Desmoulins, Isabelle
    Rouge, Thibault De La Motte
    Bachelot, Thomas
    Ferrero, Jean-Marc
    Eymard, Jean-Christophe
    Dalenc, Florence
    Mouret-Reynier, Marie-Ange
    Petit, Thierry
    Chevrot, Michael
    Courtinard, Coralie
    Uwer, Lionel
    Frenel, Jean-Sebastien
    Baldini, Capucine
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Outcome of Young Patients with Breast Cancer Outside of Clinical Trials
    El Saghir, N.
    Assi, H.
    Jaber, S.
    Nachef, Z.
    Mikdashi, H.
    El-Asmar, N.
    Houjeij, M.
    Saad, G. Abi
    Jamali, F.
    Abbas, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S58 - S58
  • [44] Phase II and III clinical trials of toremifene for metastatic breast cancer
    Vogel, CL
    ONCOLOGY-NEW YORK, 1998, 12 (03): : 9 - 13
  • [45] The role of biologic therapy in phase II breast cancer clinical trials
    Patel, K.
    Kamal, A.
    Zhang, T.
    Schneider, A.
    Hamilton, E. P.
    Peppercorn, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer
    Pusztai, Lajos
    Anderson, Keith
    Hess, Kenneth R.
    CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6080 - 6086
  • [47] LONG TERM SURVIVAL OF EARLY AND LOCALLY ADVANCED BREAST CANCER PATIENTS TREATED OUTSIDE OF CLINICAL TRIALS
    El Saghir, N. S.
    El-Asmar, N. S.
    Abboud, M.
    Houjeij, M.
    Kassem, Z.
    Abbas, J.
    Hussein, M.
    Saad, G. Abi
    ANNALS OF ONCOLOGY, 2010, 21 : 94 - 95
  • [48] The impact of sarcopenia in patients enrolled in early phase cancer trials
    Lewis, A. R.
    Green, A.
    Weaver, J. M. J.
    Mansoor, W.
    Cook, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S496 - S496
  • [49] Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis
    Costa, R.
    Gill, N.
    Rademaker, A. W.
    Carneiro, B. A.
    Chae, Y. K.
    Kumthekar, P.
    Gradishar, W. J.
    Kurzrock, R.
    Giles, F. J.
    CANCER TREATMENT REVIEWS, 2017, 55 : 10 - 15
  • [50] Efficacy of immunotherapy agents in patients with metastatic breast cancer treated in phase I clinical trials.
    Kagihara, Jodi A.
    Weiss, Jennifer A.
    Nicklawsky, Andrew
    Gao, Dexiang
    Borges, Virginia F.
    Kabos, Peter
    Jimeno, Antonio
    Diamond, Jennifer R.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 69 - 70